Liminatus Pharma (LIMN) & The Competition Head to Head Contrast

Liminatus Pharma (NASDAQ:LIMN) is one of 862 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Liminatus Pharma to related businesses based on the strength of its dividends, valuation, profitability, risk, institutional ownership, analyst recommendations and earnings.

Valuation and Earnings

This table compares Liminatus Pharma and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Liminatus Pharma	N/A	-$10.21 million	-9.95
Liminatus Pharma Competitors	$725.66 million	$15.88 million	-11.83

Liminatus Pharma’s competitors have higher revenue and earnings than Liminatus Pharma. Liminatus Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Liminatus Pharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Liminatus Pharma Competitors	-9,375.31%	-127.87%	-33.50%

Risk & Volatility

Liminatus Pharma has a beta of 5.34, indicating that its share price is 434% more volatile than the S&P 500. Comparatively, Liminatus Pharma’s competitors have a beta of 1.23, indicating that their average share price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Liminatus Pharma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1	0	0	0	1.00
Liminatus Pharma Competitors	9317	14842	44399	1481	2.54

As a group, “Biotechnology” companies have a potential upside of 56.03%. Given Liminatus Pharma’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Liminatus Pharma has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

48.0% of shares of all “Biotechnology” companies are held by institutional investors. 19.4% of Liminatus Pharma shares are held by insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Liminatus Pharma competitors beat Liminatus Pharma on 8 of the 13 factors compared.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.